Sai Parenteral's IPO 2026: GMP, Review, Price Band, Dates & Should You Apply?

Sai Parenteral's IPO is a book-built issue worth ₹408.79 crore, consisting of a fresh issue of ₹285.00 crore and an offer for sale of ₹123.79 crore. The IPO opens on March 24, 2026, and closes on March 27, 2026, with tentative listing on BSE and NSE on April 2, 2026.

The IPO is priced in the range of ₹372 to ₹392 per share, with a minimum investment of ₹14,896 for retail investors. Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company engaged in research, development, and manufacturing.

Let us understand the Sai Parenteral's IPO in detail.

Sai Parenteral's IPO – Key Details 2026

The following are some of the important and key details about Sai Parenteral's IPO.

Sai Parenteral's IPO Timeline

The following table explains the tentative IPO schedule.

Sai Parenteral's IPO Lot Size & Investment

The following table shows the minimum and maximum investment required.

About Sai Parenteral's Ltd. Business Operations

Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.

The company operates in two key segments:

• Branded Generic Formulations
• Contract Development and Manufacturing Organisation (CDMO) products and services

Its product portfolio covers multiple therapeutic areas including:

• Cardiovascular
• Neuropsychiatry
• Anti-diabetic
• Respiratory health
• Antibiotics
• Gastroenterology
• Vitamins, minerals and supplements (VMS)
• Analgesics and dermatology

The company offers products across dosage forms such as injectables, tablets, capsules, liquid orals, and ointments.

Business Segments of Sai Parenteral's Ltd.

The following are the core operating segments of Sai Parenteral's Ltd.

Branded Generic Formulations

• Focus on domestic pharmaceutical formulations across multiple therapeutic categories

CDMO Business

• Provides contract development and manufacturing services for domestic and international markets

Global Presence & Operations

The following highlights the company’s operational scale.

• Serves central and state government agencies, pharmaceutical companies, hospitals, and distributors
• Entered exports in FY 2023 after acquiring internationally accredited facilities
• Supplies to Australia, New Zealand, Southeast Asia, the Middle East, and Africa
• Operates five manufacturing facilities in India
• Subsidiary facility located in Ongole, Andhra Pradesh
• Workforce of 298 full-time employees as of December 31, 2025

Competitive Strengths of Sai Parenteral's Ltd.

The following are the key strengths of the company:

• Diversified generic formulations player with established track record
• Strategically located and accredited manufacturing facilities
• Strong focus on CDMO business
• Well-established distribution network in India and overseas
• Track record of value-accretive acquisitions
• Experienced promoters and senior management

Sai Parenteral's Ltd. – Financial Performance

The following table shows restated consolidated financials.Amount in ₹ Crore

Key insight: The company shows growth in income and profitability over the reported periods.

Key Performance Indicators (KPI)

The following table highlights important valuation and profitability metrics:

Objects of the Issue

The following explains how IPO proceeds will be used.

Fresh capital will be used towards expansion, R&D, debt repayment, and business growth initiatives.

Valuation Snapshot

The following table shows EPS and P/E comparison.

Risks to Consider

Investors should be aware of the following risks.

• Dependence on pharmaceutical formulations and CDMO business
• Exposure to regulatory and compliance requirements
• Working capital and expansion-related risks
• Competitive pharmaceutical industry landscape

Summary

Sai Parenteral's Ltd. operates in the pharmaceutical formulations and CDMO space with a diversified product portfolio and growing international presence. The company has multiple manufacturing facilities and serves a wide customer base across domestic and global markets.

The IPO consists of a mix of fresh issue and OFS, with proceeds allocated towards capacity expansion, R&D, debt repayment, and strategic investments. Financial performance reflects growth in income and profitability over the years.

This IPO may appeal to investors looking for:

• Exposure to the pharmaceutical formulations sector
• A company with diversified therapeutic portfolio
• Participation in CDMO and export-driven growth
•  

Disclaimer

This content is for informational and educational purposes only and does not constitute investment advice. UnlistedKraft is not responsible for any losses arising from investment decisions based on this content. Readers should conduct their own research and consult qualified professionals before investing. IPO is expected to list on April 2, 2026, on BSE and NSE.

Frequently Asked Questions

What is Sai Parenteral's IPO?

Sai Parenteral's IPO is a main-board IPO of ₹408.79 crore, consisting of a fresh issue and offer for sale, priced at ₹372–₹392 per share.

When does the Sai Parenteral's IPO open?

The Sai Parenteral's IPO opens on March 24, 2026, and closes on March 27, 2026.

What is the lot size of Sai Parenteral's IPO?

The minimum lot size of Sai Parenteral's IPO is 38 shares.

Is Sai Parenteral's Ltd. profitable?

Yes, Sai Parenteral's Ltd. has reported profits across the reported financial periods including FY23, FY24, FY25, and the latest interim period.

Who are the promoters of Sai Parenteral's Ltd.?

The promoters of Sai Parenteral's Ltd. include Anil Kumar Karusala, Vijitha Gorrepati, and Karusala Aruna.

What does Sai Parenteral's Ltd. do?

Sai Parenteral's Ltd. is engaged in pharmaceutical formulations, offering branded generics and CDMO services across multiple therapeutic segments and dosage forms.

Author: Komal Bhatt

Komal Bhatt is a finance content writer at InvestKraft, specialising in research-based articles on financial products, markets, and investment opportunities, including unlisted shares. She holds a Master’s degree in Commerce from the University of Delhi, providing a strong academic foundation in finance and business.

With over three years of experience in digital content, she focuses on simplifying complex financial topics into clear, accurate, and reader-friendly information. Her background includes creating content related to finance certifications such as wealth management and NISM programs, strengthening her understanding of financial markets and investor education.